

# Fasiha Kanwal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/820699/publications.pdf>

Version: 2024-02-01

138  
papers

8,297  
citations

61984

43  
h-index

49909

87  
g-index

139  
all docs

139  
docs citations

139  
times ranked

9870  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2017, 153, 996-1005.e1.	1.3	680
2	Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1342-1359.e2.	4.4	634
3	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 1828-1837.e2.	1.3	490
4	Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 124-131.e1.	4.4	471
5	Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. <i>BMC Medical Research Methodology</i> , 2018, 18, 1.	3.1	390
6	Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. <i>Gastroenterology</i> , 2017, 152, 812-820.e5.	1.3	339
7	Global epidemiology and burden of HCV infection and HCV-related disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 122-132.	17.8	317
8	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 161, 1657-1669.	1.3	229
9	Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 594-601.e1.	4.4	215
10	Houston Consensus Conference on Testing for <i>Helicobacter pylori</i> Infection in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 992-1002.e6.	4.4	189
11	Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. <i>Hepatology</i> , 2020, 71, 44-55.	7.3	188
12	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 808-819.	7.3	170
13	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 61-71.e15.	4.4	159
14	A New Laboratory-Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients With Hepatitis C and Cirrhosis. <i>Gastroenterology</i> , 2014, 146, 1249-1255.e1.	1.3	156
15	Trends in the Burden of Nonalcoholic Fatty Liver Disease in United States Cohort of Veterans. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 301-308.e2.	4.4	136
16	The Quality of Care Provided to Patients With Cirrhosis and Ascites in the Department of Veterans Affairs. <i>Gastroenterology</i> , 2012, 143, 70-77.	1.3	133
17	Efficacy of Psychosocial Interventions in Inducing and Maintaining Alcohol Abstinence in Patients With Chronic Liver Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 191-202.e4.	4.4	126
18	Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting. <i>American Journal of Gastroenterology</i> , 2015, 110, 10-14.	0.4	110

#	ARTICLE	IF	CITATIONS
19	An Explicit Quality Indicator Set for Measurement of Quality of Care in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 709-717.	4.4	109
20	Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 273-281.e1.	4.4	106
21	Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 66, 355-362.	3.7	104
22	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. <i>Journal of Hepatology</i> , 2019, 70, 639-647.	3.7	101
23	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 1787-1797.	7.3	92
24	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Gastroenterology</i> , 2019, 156, 2149-2157.	1.3	90
25	Increased Risk of Pancreatic Adenocarcinoma After Acute Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1143-1150.e1.	4.4	85
26	Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans. <i>American Journal of Gastroenterology</i> , 2014, 109, 1427-1435.	0.4	84
27	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. <i>Hepatology</i> , 2017, 65, 777-788.	7.3	83
28	Increasing Health Care Burden of Chronic Liver Disease Compared With Other Chronic Diseases, 2004-2013. <i>Gastroenterology</i> , 2018, 155, 719-729.e4.	1.3	81
29	Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 1425-1433.	3.7	81
30	Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. <i>Hepatology</i> , 2021, 74, 3316-3329.	7.3	75
31	Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1714-1720.	2.3	72
32	Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1207-1217.e4.	4.4	71
33	Early Impact of COVID-19 on Solid Organ Transplantation in the United States. <i>Transplantation</i> , 2020, 104, 2221-2224.	1.0	68
34	Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. <i>Hepatology</i> , 2014, 60, 1871-1878.	7.3	67
35	Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. <i>Journal of Viral Hepatitis</i> , 2019, 26, 596-602.	2.0	67
36	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 75, 1420-1428.	7.3	65

#	ARTICLE	IF	CITATIONS
37	Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1677-1678.	4.4	63
38	Patient-reported outcomes in cirrhosis: A scoping review of the literature. <i>Hepatology</i> , 2018, 67, 2375-2383.	7.3	62
39	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2016, 63, 291-299.	5.8	60
40	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 9-18.	4.4	58
41	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	1.3	58
42	AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. <i>Hepatology</i> , 2022, 76, 819-853.	7.3	56
43	New Diagnosis of Chronic Pancreatitis: Risk of Missing an Underlying Pancreatic Cancer. <i>American Journal of Gastroenterology</i> , 2014, 109, 1824-1830.	0.4	52
44	Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. <i>Hepatology</i> , 2018, 67, 2085-2095.	7.3	50
45	Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. <i>Nutrients</i> , 2019, 11, 613.	4.1	48
46	Trends in Outcomes for Marginal Allografts in Liver Transplant. <i>JAMA Surgery</i> , 2020, 155, 926.	4.3	48
47	Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 252-259.	4.4	47
48	Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. <i>JAMA Network Open</i> , 2020, 3, e2023780.	5.9	45
49	The Quality of Care Provided to Patients With Varices in the Department of Veterans Affairs. <i>American Journal of Gastroenterology</i> , 2014, 109, 934-940.	0.4	42
50	Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 98-106.	0.4	36
51	Risk factors for HCC in contemporary cohorts of patients with cirrhosis. <i>Hepatology</i> , 2023, 77, 997-1005.	7.3	36
52	Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 949.	5.1	35
53	Improving Quality of Health Care for Patients With Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 1204-1207.	1.3	34
54	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. <i>BMJ Open</i> , 2019, 9, e026726.	1.9	34

#	ARTICLE	IF	CITATIONS
55	On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 865-870.	4.4	33
56	Risk Factors for Cirrhosis in Contemporary Hepatology Practices—Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. <i>Gastroenterology</i> , 2020, 159, 376-377.	1.3	32
57	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	8.6	30
58	Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2713-2718.	2.3	28
59	Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. <i>Digestive Diseases and Sciences</i> , 2017, 62, 526-533.	2.3	27
60	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 530-532.	0.4	27
61	The End of Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 533-536.	4.4	26
62	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	7.3	26
63	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	3.4	25
64	Clinical Factors Associated With Lack of Serological Response to SARS-CoV-2 Messenger RNA Vaccine in Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 123-126.	2.4	25
65	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 739-747.e8.	4.4	24
66	Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1678-1680.	4.4	23
67	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2439-2451.	2.3	23
68	Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 115-122.e10.	4.4	21
69	Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. <i>Journal of Hepatology</i> , 2022, 76, 294-301.	3.7	20
70	Integrated Model for Patient-Centered Advanced Liver Disease Care. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1015-1024.	4.4	19
71	Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. <i>Digestive Diseases and Sciences</i> , 2021, 66, 912-916.	2.3	19
72	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62.	3.7	19

#	ARTICLE	IF	CITATIONS
73	Quality of Care in the Cirrhotic Patient. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e166.	2.5	18
74	Nutrition in Alcoholic Liver Disease. <i>Clinics in Liver Disease</i> , 2019, 23, 99-114.	2.1	18
75	Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 76, 251-274.	7.3	18
76	Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1381-1383.	4.4	16
77	Hepatitis C and Risk of Nonhepatic Malignancies. <i>Clinics in Liver Disease</i> , 2017, 21, 543-554.	2.1	15
78	Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. <i>JAMA Network Open</i> , 2020, 3, e2021173.	5.9	15
79	Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1443-1450.e6.	4.4	13
80	Unconscious Bias in Peer Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 419-420.	4.4	13
81	Decreasing Mortality in Patients Hospitalized With Cirrhosis. <i>Gastroenterology</i> , 2015, 148, 897-900.	1.3	12
82	Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 310-312.	4.4	12
83	Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 327-333.e1.	4.4	11
84	Implementation of a Population-Based Cirrhosis Identification and Management System. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1182-1186.e2.	4.4	11
85	Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1858-1866.e6.	4.4	11
86	Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 422-424.	8.1	11
87	Why We Should Be Willing to Pay for Hepatitis C Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1711-1713.	4.4	10
88	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. <i>Antiviral Research</i> , 2020, 174, 104698.	4.1	10
89	Oral Health and the Altered Colonic Mucosa-Associated Gut Microbiota. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2981-2991.	2.3	10
90	Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. <i>Microbial Ecology</i> , 2021, , 1.	2.8	10

#	ARTICLE	IF	CITATIONS
91	Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. <i>Transplantation Direct</i> , 2022, 8, e1313.	1.6	10
92	Pay for Performance in Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2042-2047.	4.4	8
93	The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1180-1185.	2.3	8
94	A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus. <i>Health Services Research</i> , 2018, 53, 2547-2566.	2.0	8
95	Collaborative Care for Depression in Chronic Hepatitis C Clinics. <i>Psychiatric Services</i> , 2016, 67, 1076-1082.	2.0	7
96	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	3.0	7
97	Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 5695.	3.3	6
98	Improving quality of care in patients with cirrhosis. <i>Clinical Liver Disease</i> , 2013, 2, 123-124.	2.1	5
99	The HCV Treatment Cascade: Race Is a Factor to Consider. <i>Journal of General Internal Medicine</i> , 2019, 34, 1949-1951.	2.6	5
100	Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 223-225.e3.	4.4	5
101	Primary Prophylaxis of Variceal Bleeding. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 783-794.	2.2	4
102	Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. <i>Hepatology</i> , 2022, 76, 546-548.	7.3	4
103	Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2030-2037.	2.3	3
104	Use of Hyams Law, R Criteria, and nR Criteria to Predict Acute Liver Failure or Transplantation in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2015, 148, 452.	1.3	3
105	Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 459-461.	4.4	3
106	Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1470-1477.	2.3	3
107	Covering the Year in CGH: 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3-10.	4.4	3
108	Retrospective analysis of long-term outcome 10 years after liver transplantation for Wilson disease: experience over three decades. <i>Transplant International</i> , 2020, 33, 925-935.	1.6	3

#	ARTICLE	IF	CITATIONS
109	NAFLD and HCC: Time to Bridge the Gap. <i>Hepatology</i> , 2021, 74, 2336-2338.	7.3	3
110	The Top Five Reasons You Should Publish in <i>Clinical Gastroenterology and Hepatology</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 164-165.	4.4	2
111	The Influence of Gut and Tumor Microbiome on Pancreatic Cancer Outcomes. <i>Gastroenterology</i> , 2020, 159, 1184-1185.	1.3	2
112	Elevated serum sodium in recipients of liver transplantation has a substantial impact on outcomes. <i>Transplant International</i> , 2021, 34, 1971-1983.	1.6	2
113	Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 628-640.	2.0	2
114	Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. <i>Liver Transplantation</i> , 2023, 29, 15-25.	2.4	2
115	The Art and Science of Managing Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2029-2030.	4.4	1
116	Reply to: "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients". <i>Journal of Hepatology</i> , 2017, 67, 884-885.	3.7	1
117	Reply to: "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection". <i>Journal of Hepatology</i> , 2017, 67, 886-887.	3.7	1
118	Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure". <i>Journal of Hepatology</i> , 2019, 71, 638-639.	3.7	1
119	Aggressive utilization of liver allografts: Improved outcomes over time. <i>Clinical Transplantation</i> , 2020, 34, e13860.	1.6	1
120	Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 701-711.	3.7	1
121	Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS-CoV-2 Infection. <i>Liver Transplantation</i> , 2022, 28, 127-130.	2.4	1
122	Marginal Allografts in Liver Transplantation Have a Limited Impact on Length of Stay. <i>Clinical Transplantation</i> , 2021, , e14544.	1.6	1
123	Significant improvements, but consistent disparities in survival for African Americans after liver transplantation. <i>Clinical Transplantation</i> , 2022, , e14646.	1.6	1
124	Response to Li et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 774.	0.4	0
125	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 487-488.	4.4	0
126	NAFLD-Related HCC: How Should the Shift in Epidemiology Change Our Prevention and Surveillance Strategies?. <i>Current Hepatology Reports</i> , 2017, 16, 26-32.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Anniversary Tribute From the Editors of Clinical Gastroenterology and Hepatology. Clinical Gastroenterology and Hepatology, 2017, 15, 1823-1827.	4.4	0
128	Hepatology in a changing health care landscape: A call for health services research. Hepatology, 2018, 68, 1154-1162.	7.3	0
129	Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?" Journal of Hepatology, 2019, 70, 1301-1302.	3.7	0
130	Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure" Journal of Hepatology, 2020, 73, 1579-1580.	3.7	0
131	A learning curve in using orphan liver allografts for transplantation. Clinical Transplantation, 2020, 34, e13821.	1.6	0
132	Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure" Journal of Hepatology, 2021, 74, 477.	3.7	0
133	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Clinical Liver Disease, 2021, 17, 308-308.	2.1	0
134	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
135	Presentation of the AGA William Beaumont Prize in Gastroenterology to David Y. Graham, MD. Gastroenterology, 2021, 161, 333-335.	1.3	0
136	Comparable survival for hepatitis C-related hepatocellular carcinoma after liver transplantation irrespective of viremic status. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
137	Reply. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
138	Reply. Hepatology, 2022, 76, E50-E50.	7.3	0